opinion
express
argument
employ
public
sole
respons
author
necessarili
reflect
oecd
govern
member
countri
alarm
increas
emerg
antibiot
resist
among
pathogen
worldwid
becom
seriou
threat
abil
treat
infecti
diseas
accord
world
health
organ
extens
use
antibiot
livestock
produc
promot
spread
new
resist
strain
zoonot
concern
increas
foodborn
ill
human
caus
signific
econom
burden
healthcar
system
furthermor
consum
prefer
meatpoultryfish
produc
without
use
antibiot
shape
today
market
demand
view
inevit
one
health
initi
human
need
reduc
use
antibiot
turn
altern
improv
mean
control
diseas
vaccin
prophylact
besid
intens
research
focus
novel
therapeut
molecul
strategi
reli
heavili
avail
costeffect
effici
scalabl
product
platform
allow
largevolum
manufactur
vaccin
antibodi
biopharmaceut
within
context
plantbas
platform
product
recombin
therapeut
protein
offer
signific
advantag
convent
express
system
includ
lack
anim
pathogen
low
product
cost
fast
turnaround
respons
time
rapid
nearlyunlimit
scalabl
also
dri
leav
seed
store
room
temperatur
lengthi
period
without
loss
recombin
protein
plant
express
system
potenti
offer
lucr
benefit
develop
edibl
vaccin
prophylact
would
requir
cold
chain
storag
transport
could
administ
mass
volum
minim
process
sever
biotechnolog
compani
current
develop
adopt
plantbas
platform
commerci
product
recombin
protein
therapeut
manuscript
outlin
challeng
process
livestock
immun
well
current
plant
biotechnolog
develop
aim
address
challeng
health
wellb
foodbear
anim
major
preoccup
livestock
poultri
fish
produc
endem
diseas
epidem
outbreak
repres
signific
financi
risk
produc
due
loss
anim
product
anim
market
reduct
feed
convers
effici
potenti
risk
consum
contamin
food
import
public
health
concern
signific
invest
made
agrifood
industri
ensur
safe
food
product
nevertheless
estim
million
case
ill
due
consumpt
food
contamin
known
pathogen
occur
annual
unit
state
thu
critic
import
primari
produc
ensur
health
livestock
public
health
anim
welfar
busi
profit
reason
key
minim
anim
morbid
mortal
employ
good
product
practic
best
practic
vari
accord
product
system
landbas
agricultur
typic
includ
provis
uncontamin
feed
water
adequ
ventil
air
qualiti
biosecur
robust
surveil
anim
health
judici
use
antimicrobi
agent
parasiticid
diseas
prevent
treatment
warrant
promin
anim
health
toolbox
antibiot
reason
assum
avail
antibiot
becom
increasingli
constrain
legitim
public
alarm
loom
spectr
catastroph
antibiot
resist
human
medicin
translat
action
farm
level
furthermor
develop
antibiot
resist
progress
reduc
antibiot
therapi
option
avail
veterinarian
restrict
use
veterinari
antibiot
result
marketdriven
forc
consum
increasingli
demand
antibioticfre
food
polici
govern
code
practic
veterinari
practition
promot
judici
use
within
evolv
environ
newli
develop
vaccin
immunotherapeut
agent
offer
potenti
lessen
need
antibiot
diseas
control
offer
veterinari
practition
much
need
tool
global
market
anim
vaccin
estim
current
worth
billion
anticip
grow
compound
annual
growth
rate
valu
billion
efficaci
vaccin
eas
employ
overal
benefit
term
increas
product
must
competit
diseas
manag
option
recent
advanc
immunolog
biotechnolog
specif
develop
method
produc
potent
vaccin
costeffect
use
plantbas
bioreactor
potenti
make
vaccin
even
attract
proposit
furthermor
case
vaccin
use
prevent
diseas
product
antibodi
plant
passiv
immunotherapi
infecti
diseas
control
hold
great
promis
review
paper
cover
anim
immun
essenti
present
latest
develop
plant
biotechnolog
product
veterinari
therapeut
specif
aspect
discuss
includ
highlevel
recombin
protein
product
plantbas
system
abil
use
unpurifi
materi
treatment
possibl
oral
rather
parenter
deliveri
low
cost
proteinvaccin
product
short
turnaround
time
concept
largescal
manufactur
abil
stack
gene
encod
antigen
adjuv
creat
potent
multitarget
vaccin
singl
prepar
contrast
human
newborn
farm
anim
foal
piglet
calv
lamb
kid
depend
total
companion
anim
kitten
puppi
almost
complet
upon
uptak
colostr
antibodi
system
matern
immun
pathogen
intestin
uptak
occur
via
endocytosi
involv
neonat
fc
receptor
fcrn
highest
immedi
birth
declin
rapidli
within
h
intestin
cell
matur
intestin
flora
establish
time
cessat
macromolecular
transport
gut
closur
vari
speci
immunoglobulin
type
rang
h
age
multipar
anim
speci
degre
passiv
immun
heterogen
litter
among
member
litter
variabl
colostr
absorpt
true
piglet
puppi
kitten
whose
level
passiv
antibodi
maximum
h
birth
time
immunoglobulin
concentr
declin
serum
newborn
anim
halflif
depend
immunoglobulin
isotyp
speci
vari
day
iga
igm
approxim
day
canin
equin
igg
respect
affin
igg
endotheli
fcrn
like
account
differ
observ
serum
halflif
among
speci
differ
igg
subclass
also
growth
rate
anim
influenc
rate
declin
level
maternallyderiv
antibodi
particularli
clear
canin
speci
dog
belong
rapid
growth
breed
elimin
maternallyderiv
antibodi
quickli
slowgrowth
breed
addit
differ
uptak
matern
antibodi
degre
passiv
immun
equal
tissu
instanc
colostr
immun
protect
young
anim
system
infect
first
month
life
wherea
respiratori
tract
mucu
protect
week
shortli
parturit
drastic
chang
occur
composit
colostrum
drastic
drop
igg
iga
domest
anim
drop
iga
less
pronounc
igg
iga
becom
import
immunoglobulin
milk
milk
antibodi
essenti
protect
young
anim
intestin
infect
iga
milk
dimer
secretori
iga
siga
dimer
iga
secret
mammari
gland
tissu
plasma
cell
bind
j
chain
polymer
immunoglobulin
receptor
pigr
express
basolater
site
alveolar
epitheli
cell
endocytos
transcytos
exocytos
interstiti
space
cleavag
receptor
extracellular
kda
part
pigr
except
carbohydraterich
incorpor
ig
molecul
bound
secretori
compon
sc
endow
siga
resist
proteolyt
degrad
rumin
igg
concentr
remain
higher
iga
specif
enrich
colostrum
milk
level
approxim
time
higher
iga
role
fcrn
transport
complet
clarifi
wean
lactogen
protect
disappear
make
young
anim
highli
suscept
infect
enteropathogen
pathogen
either
colon
mucosa
invad
host
mucos
surfac
optim
protect
pathogen
often
involv
induct
pathogenspecif
siga
infect
site
optim
vaccin
induc
robust
mucos
siga
immun
respons
parenter
vaccin
typic
induc
igg
respons
particularli
effect
type
infect
best
way
elicit
pathogenspecif
siga
activ
local
mucosaassoci
lymphoid
tissu
malt
site
colon
invas
mucos
vaccin
necess
administ
vaccin
mucos
site
relat
pathogen
tropism
highlight
compartment
mucos
immun
system
exampl
stimul
gutassoci
lymphoid
tissu
galt
induc
protect
siga
respons
respiratori
tract
induct
immun
respons
nasal
mucosa
fail
induc
intestin
protect
take
account
induct
mucos
immun
requir
vaccin
pass
sever
physiolog
barrier
defenc
mechan
reach
induct
site
mucos
immun
system
whether
upon
oral
intranas
rectal
urogenit
administr
vaccin
surmount
mucu
antimicrobi
peptid
travers
epitheli
barrier
case
oral
administr
vaccin
also
need
surviv
low
ph
stomach
digest
enzym
bile
salt
transport
via
peristalsi
galt
furthermor
vaccin
trigger
protect
mucos
immun
instead
toler
domin
respons
mode
mucos
immun
system
without
caus
sever
inflamm
fuse
vaccin
antigen
antibodi
antibodi
fragment
target
subunit
vaccin
antigensampl
rout
mucos
surfac
transcytot
epitheli
receptor
could
drastic
improv
oral
vaccin
efficaci
limit
number
mucos
vaccin
shown
meet
criteria
consequ
intern
licens
licens
base
liveattenu
pathogen
inactiv
pathogen
mucos
subunit
vaccin
licens
far
wherea
mani
particl
system
viruslik
particl
vlp
see
text
particl
shown
immunogen
mice
via
oral
rout
almost
none
success
larger
anim
human
could
explain
longer
intestin
transit
time
particl
reach
induct
site
larger
mammalian
speci
contrast
mice
result
larger
anim
small
portion
particl
reach
galt
result
fewer
particl
taken
cell
subsequ
low
induct
intestin
mucos
immun
respons
contrast
particul
system
solubl
antigen
immunogen
gener
induc
toler
upon
mucos
administr
even
mice
howev
solubl
antigen
shown
immunogen
via
mucos
rout
cholera
toxin
ct
thermolabil
enterotoxin
lt
b
subunit
ctb
ltb
purifi
fimbria
enterotoxigen
e
coli
pig
antigen
character
abil
bind
receptor
enterocyt
small
intestin
taken
epitheli
cell
follow
induct
antigenspecif
iga
respons
wherea
microgram
quantiti
ctb
ltb
immunogen
given
milligram
amount
oral
rout
advantag
rout
vaccin
antigen
administ
feed
elimin
need
restrain
livestock
administr
allow
use
lesspurifi
antigen
deliveri
veterinari
vaccin
gener
inject
although
variat
depend
upon
anim
speci
immun
manag
practic
age
anim
exampl
virtual
vaccin
cattl
deliv
parenter
use
poultri
deliv
inject
oral
aerosol
ultim
rout
deliveri
dictat
larg
variou
manag
system
employ
well
eas
handl
individu
anim
number
issu
associ
invas
vaccin
deliveri
foodproduc
anim
one
econom
loss
associ
trim
area
surround
inject
site
lesion
mani
veterinari
vaccin
extrem
proinflammatori
natur
exampl
clostridi
vaccin
use
cattl
deliv
subcutan
vaccin
tend
result
larg
swell
persist
month
hand
intramuscular
inject
result
overt
swell
caus
signific
tissu
damag
near
inject
site
cost
associ
carcass
trim
estim
per
anim
addit
uncommon
needl
break
intramuscular
deliveri
caus
problem
process
well
retail
level
inject
antigen
result
tissu
damag
kill
vaccin
also
contain
strong
adjuv
contribut
damag
adjuv
significantli
increas
cost
vaccin
also
dictat
qualiti
magnitud
immun
respons
former
bias
toward
immun
respons
adjuv
current
use
suitabl
inject
compat
mucos
deliveri
maintain
efficaci
inject
vaccin
requir
proper
refriger
storag
need
challeng
extens
livestock
oper
especi
develop
nation
deliveri
modifi
live
viral
vaccin
via
intranas
rout
drink
water
effect
howev
live
bacteri
vaccin
commonli
use
part
due
use
antibiot
industri
mucos
vaccin
avail
swine
includ
bordetella
bronchiseptica
shown
result
enhanc
siga
product
follow
singl
administr
intranas
rout
novel
adjuv
platform
consist
cpg
odn
polyphosphazen
cation
innat
defens
regul
peptid
idr
also
test
efficaci
swine
model
shown
provid
long
durat
immun
bordetella
pertussi
mice
follow
singl
intranas
administr
interestingli
formul
also
work
presenc
matern
antibodi
make
ideal
mucos
immun
neonat
present
avail
commerci
vaccin
target
respiratori
tract
via
intranas
aerosol
conjunctiv
applic
live
attenu
vector
vaccin
nevertheless
potenti
use
protein
vaccin
consist
dead
microorgan
subunit
virul
factor
immun
respiratori
tract
experiment
demonstr
use
particul
deliveri
system
either
lipophil
mucoadhes
andor
contain
immunomodul
molecul
ii
use
solubl
conjug
antigen
epitop
carrier
target
antigen
mucosa
respiratori
tract
iii
use
solubl
antigen
often
adjuv
need
strong
mucos
immun
respons
wherea
experiment
result
promis
mani
studi
dead
vaccin
immun
respiratori
tract
commerci
advers
reaction
hamper
develop
inde
anaphylaxi
due
impur
bell
palsi
due
vaccin
compon
describ
result
anim
studi
suggest
intranas
rout
may
facilit
transport
protein
inactiv
vaccin
live
virus
particl
central
nervou
system
therefor
candid
vaccin
target
respiratori
tract
mucosa
thoroughli
evalu
advers
effect
oral
vaccin
call
edibl
vaccin
tradit
view
panacea
plantproduc
vaccin
term
use
approach
diseas
control
edibl
vaccin
offer
sever
advantag
convent
method
vaccin
deliveri
edibl
vaccin
come
contact
line
digest
tract
thu
give
potenti
stimul
mucos
system
immun
former
respons
notori
difficult
achiev
inject
bypass
mucos
barrier
part
account
reason
efficaci
inject
vaccin
intestin
pathogen
gener
quit
poor
edibl
vaccin
also
posit
implic
livestock
welfar
could
administ
directli
diet
elimin
need
confin
anim
need
breach
skin
inject
practic
promot
secondari
infect
oral
administr
vaccin
elimin
risk
injectionbas
method
pose
meat
qualiti
result
intramuscular
administr
eukaryot
organ
plant
express
synthes
process
complex
heterolog
protein
similarli
convent
fermentationbas
express
system
mammalian
insect
yeast
cell
cultur
yet
plant
varianc
pattern
protein
glycosyl
product
recombin
therapeut
protein
demonstr
varieti
plant
speci
plant
cell
contain
genom
three
type
nuclear
chloroplast
plastom
mitochondri
genom
gener
stabl
transgen
plant
produc
recombin
protein
effici
achiev
genet
engin
nuclear
genom
plastom
addit
transient
express
method
allow
quick
robust
product
recombin
protein
way
infiltr
plant
leaf
tissu
transgeneharbor
agrobacteria
recombin
protein
produc
nucleartransform
plant
synthes
cytoplasm
secret
accumul
differ
subcellular
organel
use
appropri
transit
signal
peptid
use
tissuespecif
promot
enabl
spatiallydefin
express
transgen
applic
plant
organ
leav
seed
fruit
tuber
nucleartransform
plant
offer
tremend
simplic
product
vaccin
product
seed
line
develop
propag
plant
biomass
util
tradit
agricultur
technolog
infrastructur
note
howev
nucleartransform
plant
typic
express
lower
yield
recombin
protein
compar
transient
express
requir
prolong
timefram
gener
select
transgen
seed
line
requir
measur
prevent
environment
contamin
due
transgen
flow
via
open
field
crosspollin
transgen
plant
transform
plastom
transplastom
plant
possess
sever
benefici
trait
highploidi
plastom
lack
posit
effect
transgen
silenc
lead
synthesi
typic
high
level
recombin
protein
ii
abil
express
artifici
operon
thu
allow
express
sever
protein
one
transform
step
iii
tight
transgen
contain
due
matern
inherit
plastid
dna
cultiv
plant
absenc
glycosyl
machineri
chloroplast
thwart
express
protein
glycan
essenti
structur
conform
howev
technolog
elimin
risk
addit
potenti
allergen
nonmammalian
glycan
offer
advantag
express
nonglycosyl
protein
prokaryot
origin
high
yield
recombin
protein
obtain
quickli
transient
express
system
use
viral
virusderiv
nonvir
express
vector
infiltr
leaf
tissu
agrobacterium
intermedi
host
contain
type
express
vector
agroinfiltr
common
method
use
deliveri
foreign
dna
plant
cell
main
advantag
transient
express
system
product
speed
enabl
vaccin
manufactur
within
period
short
one
month
obtain
sequenc
antigen
howev
transient
express
system
laborand
materialintens
procedur
involv
grow
agrobacterium
cultur
dilut
infiltr
cocktail
immers
plant
aerial
biomass
agrobacterium
suspens
infiltr
agrobacteria
leav
pull
releas
vacuum
allow
entri
agrobacterium
plant
tissu
manipul
add
cost
recombin
protein
product
advantag
use
wild
type
plant
view
regulatori
author
favor
us
defens
advanc
research
program
agenc
darpa
fund
major
infrastructur
project
medicago
commercialscal
product
facil
research
triangl
park
nc
kentucki
bioprocess
product
facil
owensboro
ky
also
improv
viral
vectorbas
induc
system
deploy
field
product
recent
develop
plantbas
product
system
includ
alga
moss
cellsuspens
cultur
grown
bioreactor
highlevel
contain
steril
growth
condit
advantag
system
compar
whole
plant
term
good
manufactur
practic
gmp
recombin
protein
product
though
cost
system
high
scaleup
abil
limit
although
genet
code
univers
given
nucleotid
sequenc
result
order
amino
acid
polypeptid
regardless
organ
translat
rna
messag
protein
differ
structur
depend
organ
produc
due
fact
multitud
modif
take
place
ribosom
synthesi
polypeptid
call
posttransl
modif
ptm
case
therapeut
protein
ptm
high
import
sinc
might
alter
structur
protein
function
especi
immunogen
ptm
includ
glycosyl
phosphoryl
lipid
disulfidebridg
name
promin
basic
occur
vivo
might
also
occur
downstream
process
given
therapeut
protein
differ
organ
capabl
variou
ptm
eg
bacteria
glycosyl
protein
eukaryot
organ
perform
extens
glycomodif
moreov
type
linkag
sugar
vari
consider
among
cell
type
organ
well
differ
development
stage
environment
condit
make
particular
modif
highli
divers
case
recombin
therapeut
parenter
administr
import
retain
nativ
glycosyl
pattern
avoid
shorten
halflif
unintend
immunogen
plant
glycosyl
recombin
protein
manner
differ
mammalian
cell
system
glycosyl
may
even
vari
among
plant
speci
organ
cell
type
case
even
advantag
exemplifi
recombin
glucocerebrosidas
taligluceras
alfa
made
carrot
cell
sugar
ad
produc
recombin
enzym
close
resembl
nativ
structur
termin
mannos
make
product
superior
biobett
compar
cho
cellsderiv
product
improv
glycosyl
machineri
plant
engin
produc
mammalianlik
glycan
pattern
termin
sialic
acid
make
recombin
protein
almost
indistinguish
produc
mammalian
cell
line
see
glycoengin
text
plantbas
express
system
rais
possibl
antigen
antibodi
produc
form
stabl
storag
amen
extract
purif
procedur
dri
lyophil
leafi
biomass
well
plant
storag
tissu
seed
retain
unchang
level
accumul
recombin
protein
year
normal
room
temperatur
thu
reduc
stow
cost
facilit
distribut
without
need
cold
chain
product
system
would
allow
stockpil
transgen
plant
materi
lyophil
leaf
biomass
seed
manufactur
rapidrespons
veterinari
biolog
target
pathogen
epidemiolog
relev
time
product
would
depend
speed
extract
downstream
process
purif
requir
immedi
formul
lyophil
biomass
whole
seed
administ
feed
plantbas
express
strategi
express
recombin
antigen
oil
bodi
implement
particular
protein
tag
specif
focus
overcom
complex
purif
procedur
review
although
purifi
plantderiv
biolog
function
effect
key
benefit
plant
abil
deliv
recombin
pharmaceut
minim
process
feed
flour
past
edibl
tissu
express
seed
may
also
help
protect
antigen
digest
within
intestin
tract
especi
target
format
protein
bodi
increas
deliveri
antigen
mucos
surfac
remark
format
ectop
storag
organel
sink
compart
recombin
protein
induc
tissu
adapt
storag
function
glycosyl
affect
qualiti
recombin
pharmaceut
differ
glycan
structur
potenti
influenc
stabil
subcellular
target
immunogen
pharmacokinet
biolog
activ
precis
control
optim
glycan
modif
manufactur
homogen
protein
therapeut
specif
design
glycoform
confer
superior
efficaci
therefor
becom
import
issu
product
platform
includ
mammalian
cell
mechan
nglycosyl
plant
mammal
differ
golgispecif
modif
addit
link
xylos
core
link
fucos
residu
plant
addit
link
galactos
sialic
acid
residu
mammal
therefor
strategi
control
glycosyl
recombin
protein
establish
plant
earli
subcellular
target
prevent
addit
certain
sugar
residu
glycoengin
replac
sugar
desir
counterpart
key
exampl
glycan
control
target
first
commerci
avail
plantderiv
human
therapeut
protein
taligluceras
alfa
indic
lysosom
storag
disord
call
gaucher
diseas
case
target
plant
vacuol
result
format
glycan
structur
termin
mannos
residu
promot
uptak
recombin
protein
via
mannosespecif
surfac
receptor
macrophag
engin
plant
nglycosyl
pathway
achiev
variou
approach
includ
convent
mutagenesi
homolog
recombin
rna
interfer
transgen
express
versatil
plant
product
specif
nglycoform
turn
perceiv
disadvantag
one
major
strength
plant
product
platform
addit
abolit
link
xylos
core
link
fucos
residu
complet
reconstruct
mammalian
glycosyl
pathway
plant
productspecif
design
nglycan
engin
improv
efficaci
exampl
glycoengin
plant
use
produc
glycooptim
antibodi
version
improv
pharmacokinet
properti
due
greater
receptor
affin
anoth
type
glycosyl
whose
impact
less
wide
known
mucinlik
oglycosyl
serin
threonin
hydroxyprolin
residu
latter
uniqu
plant
howev
recent
effort
address
engin
olink
glycan
suggest
oglycan
structur
may
function
adjuv
may
increas
serum
stabil
tailor
mammallik
oglycan
structur
could
also
improv
stabil
activ
protein
erythropoietin
secretori
iga
give
plant
competit
edg
product
compound
although
plant
shown
manufactur
biologicallyact
therapeut
amount
suffici
oral
administr
livestock
plantderiv
antigen
requir
formul
protect
hostil
environ
gastrointestin
tract
without
interf
immunogen
antigen
depend
plant
speci
plant
tissu
subunit
protein
express
plant
matrix
could
provid
protect
harsh
condit
elimin
need
costli
purif
provis
durabl
matrix
offer
protect
stabil
effect
beyond
harvest
upon
mucos
administr
plant
cell
matrix
effect
enhanc
resist
digest
therebi
increas
exposur
vaccin
immun
effector
cell
protect
effect
enhanc
incorpor
vaccin
protein
storag
organel
use
seed
particularli
suitabl
achiev
bioencapsul
recombin
protein
special
storag
organel
deriv
endomembran
system
allow
protein
accumul
within
protect
matrix
clear
benefit
demonstr
seedbas
product
system
recombin
protein
express
rice
pea
seed
better
protect
degrad
purifi
counterpart
upon
oral
deliveri
nevertheless
plantbas
product
could
also
neg
influenc
immunogen
antigen
influenc
antigen
fold
glycosyl
andor
interact
antigen
interf
capac
target
mucosa
latter
could
one
reason
fimbria
alfalfa
crush
leaf
biomass
ad
show
decreas
immun
respons
pig
comparison
without
plant
materi
cox
et
al
unpublish
result
scale
product
recombin
protein
transgen
transplastom
plant
much
easier
less
costli
similar
scale
mammalian
microbi
cell
simpl
reason
plant
could
consid
bioreactor
requir
sow
seed
provid
light
water
fertil
oppos
expens
upfront
invest
infrastructur
bioreactor
facil
cell
cultur
formul
complex
cell
cultur
media
therefor
scale
achiev
quickli
major
invest
singl
tobacco
plant
produc
seed
allow
fast
scaleup
within
month
tobacco
biomass
yield
reach
tonsha
singl
field
season
contain
necessari
similar
higher
yield
achiev
greenhous
high
level
accumul
desir
protein
gkg
fresh
leaf
weight
mean
kg
protein
produc
singl
hectar
menassa
et
al
unpublish
data
howev
use
stabl
transgenictransplastom
line
impli
lag
time
produc
high
express
line
obtain
seed
case
catastroph
epidem
pandem
much
faster
timelin
requir
transient
product
nicotiana
benthamiana
ideal
timelin
clone
gene
vaccin
product
week
well
system
obviat
need
product
transgen
plant
thu
eas
regulatori
framework
scale
system
wild
type
nicotiana
benthamiana
plant
grown
greenhous
infiltr
agrobacterium
cultur
contain
express
construct
requir
recombin
protein
product
infiltr
plant
harvest
day
postinfiltr
protein
purifi
sever
compani
medicago
inc
fraunhof
usa
kentucki
bioprocess
llc
adopt
system
product
influenza
vaccin
monoclon
antibodi
magnicon
system
develop
icon
genet
gmbh
allow
product
purif
monoclon
antibodi
expect
yield
mgkg
plant
fresh
weight
medicago
inc
abl
produc
million
dose
influenza
vaccin
within
one
month
squar
foot
facil
north
carolina
exampl
therapeut
protein
produc
plant
year
sinc
first
igg
antibodi
express
plant
sinc
numer
public
scientif
literatur
product
antibodi
plant
target
bacteria
cancer
target
highli
pathogen
virus
hiv
ebola
current
epidem
caus
ebola
viru
west
africa
brought
attent
plantproduc
antibodi
cocktail
cocktail
call
zmapp
recent
shown
revers
advanc
ebola
diseas
test
rhesu
macaqu
six
public
describ
product
five
approv
therapeut
antibodi
plant
tabl
therapeut
prophylact
antibodi
requir
massiv
amount
constant
basi
might
therefor
produc
econom
use
transgen
plant
rather
ferment
addit
neutral
antibodi
indic
topic
oral
microbicid
also
deliv
plant
materi
seed
demonstr
administr
pea
contain
singlechain
antibodi
high
sporozoiteneutr
activ
coccidiosi
parasit
eimeria
tenella
prevent
gastrointestin
infect
chicken
anoth
recent
studi
protect
wean
piglet
enterotoxigen
e
coli
infect
achiev
oral
administr
seed
produc
iga
wherea
simpl
protein
singl
chain
antibodi
fragment
tend
easili
express
bacteria
complex
glycoprotein
monoclon
antibodi
usual
requir
eukaryot
product
system
full
size
antibodi
tend
express
well
plant
secretori
pathway
plant
cell
contain
extens
molecular
chaperon
system
plant
particularli
benefici
product
secretori
iga
molecul
produc
four
polypeptid
compon
assembl
fulli
function
molecul
contrast
three
protein
compon
produc
plasma
cell
mammal
fourth
produc
epitheli
cell
assembl
occur
extracellular
environ
secretori
iga
assembl
also
achiev
cho
cell
carri
four
differ
transgen
effici
assembl
low
therefor
plant
offer
valuabl
superior
largescal
product
system
prefer
format
mucos
antibodi
viral
diseas
probabl
import
culprit
sever
econom
loss
livestock
product
worldwid
although
antibiot
use
treat
prevent
viral
infect
outbreak
pathogen
virus
often
predispos
infect
anim
secondari
bacteri
infect
requir
antibiot
treatment
thu
prevent
vaccin
control
primari
viral
infect
help
reduc
need
antibiot
applic
livestock
product
viruslik
particl
vlp
defin
multisubunit
protein
structur
selfassembl
compet
show
ident
highli
similar
overal
structur
correspond
nativ
virus
studi
document
high
immunogen
capac
vlp
due
display
multipl
repeat
antigen
motif
trigger
b
cell
activ
elicit
higher
antibodi
titer
compar
monomer
antigen
strong
humor
immun
respons
could
induc
vlp
without
adjuv
avoid
stimul
inflammatori
cell
respons
mani
differ
vlp
origin
phage
plant
insect
vertebr
virus
describ
summar
excel
review
includ
exampl
prepar
largescal
manufactur
vlp
bacteria
yeast
cell
insect
cell
mammalian
cell
mason
et
al
first
demonstr
express
human
hepat
b
viru
structur
protein
plant
result
envelop
vlp
budout
spheric
particl
nm
diamet
intracellular
membran
engin
envelop
hepat
b
viru
vlp
nanoparticl
allow
display
larg
foreign
antigen
develop
bival
vaccin
simultan
transient
express
four
distinct
structur
protein
bluetongu
viru
btv
led
assembl
heteromultimer
vlp
abl
elicit
strong
antibodi
respons
sheep
provid
protect
immun
btv
challeng
anoth
exampl
vlp
produc
plant
improv
transient
express
norwalk
virusderiv
nonenvelop
vlp
lettuc
contain
low
level
secondari
metabolit
use
develop
robust
plant
virusbas
product
platform
vlp
deriv
norwalk
viru
capsid
combin
scalabl
process
method
concept
produc
vlp
plant
gener
connect
idea
edibl
vaccin
howev
sever
hurdl
resolv
concept
could
implement
despit
obviou
benefit
qualiti
control
issu
precis
formul
vaccin
product
well
document
control
relev
regulatori
bodi
would
preclud
easi
onsit
product
foodfe
plant
organ
administr
vaccin
regul
avoid
insuffici
antigen
applic
vice
versa
avoid
develop
immun
toler
even
oral
administ
vlptype
vaccin
least
process
enrich
formul
appli
supervis
ensur
reproduc
result
recent
success
applic
plantbas
vlp
concept
medicago
inc
review
see
proprietari
plantbas
transient
express
system
develop
produc
vaccin
made
bud
influenza
hemagglutinin
particl
develop
platform
allow
vaccin
produc
within
one
month
disclosur
hemagglutinin
sequenc
identifi
strain
mani
influenza
type
ie
zoonot
diseas
vaccin
plantbas
vlp
develop
especi
term
lower
downstream
process
cost
fit
econom
constraint
associ
veterinari
vaccin
excel
compar
summari
differ
plantbas
vaccin
includ
express
level
immunogen
vlp
strategi
anticip
cost
given
review
scotti
rybicki
author
conclud
proof
efficaci
demonstr
sever
plantbas
vlp
vaccin
plantbas
express
system
could
well
convent
product
system
base
ferment
claim
rather
optimist
futur
plantbas
vlp
real
cost
predict
rang
concept
use
plant
express
host
veterinari
subunit
vaccin
studi
extens
within
past
two
decad
howev
studi
antigen
shown
immunogen
protect
chicken
oral
deliveri
edibl
potatobas
vaccin
develop
chicken
infecti
bronchiti
viru
ibv
slice
tuber
express
viral
glycoprotein
administ
three
dose
two
week
chicken
challeng
ibv
one
week
last
administr
oral
immun
chicken
develop
virusspecif
antibodi
respons
protect
ibv
anoth
research
group
succeed
vaccin
chicken
infecti
bursal
diseas
viru
ibdv
plantmad
protein
chicken
oral
immun
arabidopsi
crude
leaf
extract
transgen
rice
seed
protect
similar
level
achiev
commerci
inject
vaccin
recent
antigen
produc
transient
nicotiana
benthamiana
induc
neutral
antibodi
immun
chicken
use
maiz
seed
edibl
deliveri
vehicl
porcin
transmiss
gastroenter
coronaviru
tgev
extens
studi
envelop
spike
protein
use
antigen
rais
neutral
antibodi
efficaci
plantmad
vaccin
present
experi
piglet
addit
found
antigen
stabl
storag
variou
condit
author
abl
concentr
antigen
use
mill
techniqu
enterotoxigen
e
coli
etec
caus
postwean
diarrhea
piglet
target
plantmad
vaccin
major
subunit
protein
etec
fimbria
express
leav
tobacco
alfalfa
seed
barley
subunit
vaccin
shown
immunogen
partial
protect
oral
deliveri
wean
piglet
capsid
protein
antigen
epitop
footandmouth
diseas
viru
fmdv
use
substitut
part
bamboo
mosaic
viru
coat
protein
result
display
epitop
virion
retain
infect
could
propag
plant
demonstr
immun
extract
chimer
virion
intramuscular
inject
could
fulli
protect
pig
fmdv
challeng
effect
induc
humor
cellmedi
immun
respons
transgen
peanut
plant
express
bovin
rinderpest
viru
hemaglutinin
rais
immun
respons
cattl
oral
vaccin
abl
rais
virusspecif
antibodi
also
neutral
viru
vitro
immunogen
tobacco
mosaic
viru
tmv
base
vaccin
bovin
herp
viru
bhv
studi
cattl
immunogen
glycoprotein
produc
byproduct
tmvinocul
tobacco
plant
crude
plant
extract
emulsifi
oil
subsequ
inject
cattl
abl
rais
specif
humor
cellular
immun
respons
importantli
cattl
protect
bhv
similar
level
vaccin
commerci
vaccin
plantmad
subunit
vaccin
bovin
viral
diarrhea
viru
bvdv
develop
argentina
structur
protein
bvdv
express
transgen
alfalfa
fusion
peptid
target
product
antigenpres
cell
partial
purifi
antigen
administ
intramuscularli
calv
protect
bvdv
challeng
although
efficaci
treatment
classic
antibiot
declin
due
widespread
develop
antibiot
resist
among
major
pathogen
bacteria
littl
altern
fight
infect
one
novel
therapeut
option
could
use
phage
lysin
enzym
target
hydrolyz
bacteri
cell
wall
effici
kill
larg
array
bacteria
howev
due
toxic
natur
protein
product
bacteria
achiev
limit
avail
test
manufactur
lack
specif
bacterialtyp
cell
wall
structur
target
lysin
make
plant
altern
platform
product
therapeut
protein
highli
toxic
bacteria
promis
report
oey
et
al
show
target
gene
encod
lysozym
amidas
pal
tobacco
plastom
function
lysin
could
synthes
accumul
high
level
chloroplast
sever
report
describ
success
transplastom
well
transient
expressionmedi
product
short
antimicrobi
peptid
analog
secret
defensin
use
control
bacteri
viral
fungal
infect
henc
plant
repres
valuabl
product
system
antimicrobi
toxic
protein
offer
costeffect
solut
obtain
larg
quantiti
proteinac
antibiot
could
administ
feed
use
vaccin
prophylact
control
infecti
diseas
livestock
industri
grow
antibiot
applic
diminish
plant
bioreactor
compris
valuabl
option
product
recombin
protein
therapeut
anim
health
recent
year
numer
studi
demonstr
feasibl
advantag
plantbas
product
platform
variou
protein
therapeut
use
includ
complex
antibodi
subunit
vaccin
immunogen
viruslik
particl
plantmad
therapeut
product
current
cusp
wide
enter
biotechnolog
market
interact
concert
action
plant
biotechnolog
sector
veterinarian
regulatori
author
facilit
develop
novel
approach
sustain
antibioticfre
livestock
agricultur
author
declar
compet
interest
